Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01883167 · ClinicalTrials.gov registry record · Phase 1
RDEA3170 and Febuxostat Drug Interaction Study
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01883167 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 21 participants.
The verdict
NCT01883167, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study will evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD) interaction between the XO inhibitor febuxostat and the investigational URAT1 inhibitor RDEA3170 and provide information for potential future clinical studies using this combination. Combination treatment using 2 drugs with different mechanisms of action may achieve improved response and may allow the use of lower doses, resulting in fewer side effects than the use of either drug alone.
Interventions
- DRUG placebo
- DRUG RDEA3170 10 mg
- DRUG Febuxostat 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01883167
The ClinicalTrials.gov registry entry for NCT01883167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01883167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01883167 about?
NCT01883167 is a clinical study titled "RDEA3170 and Febuxostat Drug Interaction Study". This study will evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD) interaction between the XO inhibitor febuxostat and the investigational URAT1 inhibitor RDEA3170 and provide information for potential future clinical studies using this combination. Combination treatment using 2 dr...
What is the current status of trial NCT01883167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2013-06. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01883167?
The interventions under investigation include: placebo (DRUG), RDEA3170 10 mg (DRUG), Febuxostat 40 mg (DRUG).
Who is sponsoring clinical trial NCT01883167?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.